Cancer

Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer

An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression

Integration of a large cohort of transcriptome, whole genome, and ATAC-sequencing characterizes the chromatin accessibility changes in advanced prostate cancer and identifies therapy-resistant prostate cancer subtype-specific transcription factors that modulate oncogenic programs.

Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer

We discovered a group of metastatic prostate cancer patients with lower levels of DNA-DNA interactions around the Androgen Receptor (AR) gene, the main driver of prostate cancer. Interestingly, this group had an abundance of circular DNA outside of the chromosomes (extrachromosomal circular DNA (ecDNA)) that included parts of the AR gene resulting in AR gene amplification and become very active, which might explain why their cancer was resistant to treatment.

Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression

HPV-mediated Cancers

Biomarkers of HPV-negative head and neck cancer

The genomic and epigenomic landscape of double-negative metastatic prostate cancer

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer

Multiomics Characterization of Low-grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK-inhibitor Sensitivity and Therapeutic Vulnerability

LGSOC is a rare tumor subtype with high case fatality rates in patients with metastatic disease. Here, we use multiomics integration of whole-exome sequencing, RNA sequencing, and mass spectrometry–based proteomics on LGSOC cell lines to elucidate novel biomarkers and therapeutic vulnerabilities.